Dulaglutide (a GLP-1 agonist), empagliflozin, and pirfenidone each protected against Parkinson's-like features in fructose-fed rats, with combination therapy showing additive neuroprotective benefits.
Additive neuroprotectionwhen pirfenidone was combined with dulaglutide or empagliflozin, showing greater protection against Parkinson's-like features than any single drug
What the researchers found
Rats fed 10% fructose for 24 weeks developed Parkinsonian features: cognitive and motor deficits, loss of substantia nigra neurons, dopamine deficiency, and altered expression of α-synuclein, LRRK2, and parkin. These changes were accompanied by insulin resistance, dyslipidemia, neuroinflammation, and apoptosis.
All three treatments (dulaglutide 0.2 mg/kg/week SC, empagliflozin 30 mg/kg/day oral, pirfenidone 100 mg/kg/day oral) ameliorated these perturbations when given during the last 4 weeks of the fructose feeding period. Combination therapy (pirfenidone + dulaglutide or pirfenidone + empagliflozin) showed more pronounced effects than individual treatments, demonstrating additive neuroprotection.
Why it matters
The link between metabolic disease and neurodegeneration is increasingly recognized, with diabetes patients having elevated Parkinson's disease risk. This study shows that metabolic drugs — particularly the GLP-1 agonist dulaglutide — can protect against diet-induced Parkinsonian changes. This supports the growing interest in repurposing diabetes drugs for neurodegenerative diseases.
How the study worked
Rats received 10% fructose in drinking water for 24 weeks to induce metabolic and Parkinsonian features. During the last 4 weeks, different groups received empagliflozin, dulaglutide, pirfenidone, or combinations. Outcomes included behavioral testing (cognitive function and motor coordination), histological examination of substantia nigra neurons, brain biochemistry (dopamine, α-synuclein, LRRK2, parkin), and metabolic parameters (insulin resistance, lipids, inflammation, apoptosis markers).
What this study cannot tell us
This is a rat study using a fructose-induced model of Parkinsonism, which may not fully replicate human Parkinson's disease (typically caused by complex genetic and environmental factors, not diet alone). The treatment was given concurrently with the last 4 weeks of fructose — essentially a prevention rather than treatment paradigm. Specific quantitative improvements for each treatment and combination were not detailed in the abstract.
How to read the evidence
This is a preclinical rat study using a diet-induced Parkinsonism model. While it provides interesting mechanistic and pharmacological evidence, the model's relevance to human Parkinson's disease requires further validation.
When this study was published
Published in 2025, this study contributes to the current wave of research exploring metabolic drugs as neuroprotective agents, a topic of significant clinical interest.
The bigger picture
This study contributes to the rapidly expanding evidence that GLP-1 receptor agonists have neuroprotective properties beyond their metabolic effects. Clinical trials of GLP-1 drugs in Parkinson's disease are already underway, and preclinical studies like this provide mechanistic support. The metabolic-neurodegeneration connection explored here also highlights the potential for combination therapy approaches targeting both metabolic and inflammatory pathways simultaneously.
Questions still open
- Would dulaglutide or other GLP-1 drugs be effective in established Parkinson's disease models, not just prevention?
- Do the combination benefits translate to human neurodegeneration, and which combinations are most promising?
- What is the mechanism by which GLP-1 receptor activation protects dopamine-producing neurons?
Common questions
Could diabetes drugs help prevent Parkinson's disease?
How does a high-fructose diet cause Parkinson's-like symptoms?
Read the original research
Pirfenidone alone or combined with either dulaglutide or empagliflozin protects against fructose-induced Parkinsonian features in rats.
Behavioural pharmacology, 36(5), 322-336
Citation
Wahba, Alaa S; Mohamad, Hoda E; Abo-Elmatty, Dina M; Mesbah, Noha M; Wahba, Nehal S; El Azzazy, Ahmed S; Sakr, Amr T. (2025). Pirfenidone alone or combined with either dulaglutide or empagliflozin protects against fructose-induced Parkinsonian features in rats.. Behavioural pharmacology, 36(5), 322-336. https://doi.org/10.1097/FBP.0000000000000835